Global Malignant Mesothelioma Market Size, Share, Growth Analysis, By Application(Hospital Pharmacies, Retail Pharmacies), By Type(Oral, Parenteral) - Industry Forecast 2024-2031

PUBLISHED: February 26, 2024

PAGES: 157 Pages

DELIVERY TIME: 3-5 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Global Malignant Mesothelioma Market size was valued at USD 153.93 million in 2022 and is poised to grow from USD 162.70 million in 2023 to USD 253.51 million by 2031, growing at a CAGR of 5.7% in the forecast period (2024-2031).

Advocacy groups and support networks for mesothelioma patients serve as crucial pillars in the worldwide battle against this form of cancer. Their efforts are instrumental in raising awareness, promoting early detection, and furnishing vital support to individuals grappling with mesothelioma. These organizations fulfill an indispensable role through their advocacy, educational initiatives, and outreach programs, significantly enhancing patient care. By offering assistance and resources to those affected by the disease, they play a pivotal role in easing the burdens faced by patients on their difficult path.

Top-down and bottom-up approaches were used to estimate and validate the size of the Malignant Mesothelioma Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Malignant Mesothelioma Market Segmental Analysis

The global malignant mesothelioma market is segmented into three major segments i.e. by type, application, region. Based on type the market is segmented as, oral, parenteral. Based on application the market is segmented as, hospital pharmacies, retail pharmacies, oncology centers, other. Based on region the market is segmented as, North America, Europe, Asia-Pacific, MEA, and Latin America.

Drivers of the Malignant Mesothelioma Market

The surge in advancements in diagnostic methodologies plays a pivotal role in the detection of malignant mesothelioma cases. Significant enhancements in diagnostic techniques and tools have been witnessed over time, contributing to the early identification and diagnosis of this cancer. These improvements, coupled with heightened awareness among healthcare professionals and the public, have facilitated early detection and diagnosis, resulting in a higher reported incidence of cases at earlier stages.

Restraints in the Malignant Mesothelioma Market

A notable constraint in this context is the extended duration taken for diagnosis, which can impede timely intervention. Malignant mesothelioma is characterized by a prolonged latency period, often spanning several decades from initial asbestos exposure to symptom manifestation. This lengthy timeline poses a considerable challenge, delaying early diagnosis and intervention for individuals at risk.

Market Trends of the Malignant Mesothelioma Market

One of the key trends influencing the market is the aging population, which significantly contributes to the rising incidence of malignant mesothelioma. The cancer is more prevalent among older demographics, and with the global population aging, the likelihood of new cases is expected to increase. Moreover, the extended latency period for mesothelioma means that individuals exposed to asbestos earlier in life may develop the disease as they age.

Product Code: SQMIG35A2572

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Malignant Mesothelioma Market by Application

Market Overview
Hospital Pharmacies
Retail Pharmacies
Oncology Centers
Others

Global Malignant Mesothelioma Market by Type

Market Overview
Oral
Parenteral

Global Malignant Mesothelioma Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Corden Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Concordia International
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Hakko Kirin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Polaris Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MolMed
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ono Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nichi-Iko Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments